LP treatment favorably modulates a variety of surrogate endpoint biomarkers (SEBMs), including a significant reduction in bronchial Ki-67 labeling index (LI), a marker of cell proliferation on the bronchial epithelium and a key SEBM for lung cancer chemoprevention trials [9]. Here, MKI67 is linked to lung cancer.